Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Perspective Therapeutics (CATX) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Perspective Therapeutics (CATX) over the last 15 years, with Q3 2025 value amounting to 0.82.

  • Perspective Therapeutics' Equity Ratio fell 216.64% to 0.82 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.82, marking a year-over-year decrease of 216.64%. This contributed to the annual value of 0.85 for FY2024, which is 1095.85% up from last year.
  • Perspective Therapeutics' Equity Ratio amounted to 0.82 in Q3 2025, which was down 216.64% from 0.86 recorded in Q2 2025.
  • Perspective Therapeutics' 5-year Equity Ratio high stood at 0.96 for Q4 2021, and its period low was 0.77 during Q4 2023.
  • For the 5-year period, Perspective Therapeutics' Equity Ratio averaged around 0.9, with its median value being 0.9 (2023).
  • Its Equity Ratio has fluctuated over the past 5 years, first soared by 5074.26% in 2021, then tumbled by 1835.38% in 2023.
  • Perspective Therapeutics' Equity Ratio (Quarter) stood at 0.96 in 2021, then fell by 1.76% to 0.94 in 2022, then decreased by 18.35% to 0.77 in 2023, then grew by 10.96% to 0.85 in 2024, then fell by 3.59% to 0.82 in 2025.
  • Its Equity Ratio stands at 0.82 for Q3 2025, versus 0.86 for Q2 2025 and 0.86 for Q1 2025.